Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma

Abstract EN

Hepatocellular carcinoma is the fifth most common cancer worldwide and the second most lethal, following lung cancer.

Currently applied therapeutic practices rely on surgical resection, chemotherapy and radiotherapy, or a combination thereof.

These treatment options are associated with extreme adversities, and risk/benefit ratios do not always work in patients’ favor.

Anomalies of the epigenome lie at the epicenter of aberrant molecular mechanisms by which the disease develops and progresses.

Modulation of these anomalous events poses a promising prospect for alternative treatment options, with an abundance of felicitous results reported in recent years.

Herein, the most recent epigenetic modulators in hepatocellular carcinoma are recapitulated on.